Search

Your search keyword '"Inomata, Naoko"' showing total 336 results
Start Over Author "Inomata, Naoko"
336 results on '"Inomata, Naoko"'

1. A Case of Fish Sausage Anaphylaxis Induced by Epicutaneous Sensitization to Carmine Contained in Eyeshadows: The Effect of Chelation on Carmine Allergy.

Author

Yamaura, Maiko, Iwahashi, Yuriko, Hashimoto, Eri, Miura, Jun, Murayama, Yuri, Koshikawa, Sachiko, Inomata, Naoko, and Cuevas Covarrubias, Sergio A.

Subjects
ETHYLENEDIAMINETETRAACETIC acid, CHELATING agents, FISH as food, IMMUNOGLOBULIN E, SKIN tests
Abstract

Carmine is an aluminium and/or calcium‐chelated complex form of carminic acid (CA), which is derived from the Dactylopius coccus extract (cochineal), and is globally used as a red‐colourant in foods and cosmetics. Although several allergens in carmine allergies, such as CC38K, have been reported, it remains unknown whether chelation affects the allergenicity of carmine. We report a case of Japanese fish sausage (Gyoniku Sausage) anaphylaxis induced by epicutaneous sensitization to carmine contained in eyeshadows. In addition, we report on the effect of chelation on carmine allergy. A 32‐year‐old woman had experienced itching, wheals, and swelling of her eyelids immediately after applying pink eyeshadows, which contained carmine, on several occasions for 3 years. Two months ago, she developed itching, wheals, and swelling on her whole body, especially her eyelids, and dyspnea immediately after ingesting fried pink fish sausages, which contained cochineal. In skin prick tests (SPTs) with all ingredients ingested in the two episodes of anaphylaxis, only fish sausage was positive. SPT was also positive for carmine. In IgE‐immunoblotting using the eyeshadow and fish sausage, the patient serum IgE was bound to three protein bands at approximately 86, 114, and 130 kDa. In addition, IgE‐immunoblotting using the carmine showed a broad band at 86–130 kDa, which were consistent with those using the eyeshadow and fish sausage, whereas there is no band using CA. Interestingly, the protein bands using the eyeshadow and carmine were diminished by preincubation in the presence of ethylenediaminetetraacetic acid (EDTA) as a chelating agent. The results indicated that the causative allergens of carmine contained in the eyeshadows could be dechelated by EDTA, reducing its allergenicity. In conclusion, carmine contained in cosmetics can cause epicutaneous sensitisation and consequently can induce food anaphylaxis. To prevent sensitisation in carmine allergy, the effect of chelation on allergenicity of carmine should be considered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Transient improvement of urticaria induces poor adherence as assessed by Morisky Medication Adherence Scale‐8

Author

Kaneko, Sakae, Masuda, Koji, Hiragun, Takaaki, Inomata, Naoko, Furue, Masutaka, Onozuka, Daisuke, Takeuchi, Satoshi, Murota, Hiroyuki, Sugaya, Makoto, Saeki, Hidehisa, Shintani, Yoichi, Tsunemi, Yuichiro, Abe, Shinya, Kobayashi, Miwa, Kitami, Yuki, Tanioka, Miki, Imafuku, Shinichi, Abe, Masatoshi, Hagihara, Akihito, Morisky, Donald E, and Katoh, Norito

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Research, 5.1 Pharmaceuticals, Management of diseases and conditions, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 7.1 Individual care needs, Administration, Oral, Administration, Topical, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Japan, Male, Medication Adherence, Middle Aged, Surveys and Questionnaires, Urticaria, Young Adult, adherence, oral, topical, transient improvement, urticaria, Clinical Sciences, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Poor adherence to medication is a major public health challenge. Here, we aimed to determine the adherence to oral and topical medications and to analyze underlying associated factors using the translated Japanese version of Morisky Medication Adherence Scale-8 regarding urticaria treatment. Web-based questionnaires were performed for 3096 registered dermatological patients, along with a subanalysis of 751 registered urticaria patients in this study. The adherence to oral medication was significantly associated with the frequency of hospital visits. Variables that affected the adherence to topical medication included age and experience of drug effectiveness. The rate of responses that "It felt like the symptoms had improved" varied significantly among the dermatological diseases treated with oral medications. Dermatologists should be aware that adherence to the treatment of urticaria is quite low. Regular visits and active education for patients with urticaria are mandatory in order to achieve a good therapeutic outcome by increasing the adherence.

Published
2015

4. Characterization of socioeconomic status of Japanese patients with atopic dermatitis showing poor medical adherence and reasons for drug discontinuation

Author

Murota, Hiroyuki, Takeuchi, Satoshi, Sugaya, Makoto, Tanioka, Miki, Onozuka, Daisuke, Hagihara, Akihito, Saeki, Hidehisa, Imafuku, Shinichi, Abe, Masatoshi, Shintani, Yoichi, Kaneko, Sakae, Masuda, Koji, Hiragun, Takaaki, Inomata, Naoko, Kitami, Yuki, Tsunemi, Yuichiro, Abe, Shinya, Kobayashi, Miwa, Morisky, Donald E, Furue, Masutaka, and Katoh, Norihito

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Research, Behavioral and Social Science, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 7.1 Individual care needs, Management of diseases and conditions, Skin, Administration, Cutaneous, Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Alcohol Drinking, Dermatitis, Atopic, Dermatologic Agents, Employment, Female, Humans, Japan, Male, Marital Status, Medication Adherence, Middle Aged, Patient Satisfaction, Sex Factors, Surveys and Questionnaires, Treatment Outcome, Young Adult, Atopic dermatitis, Adherence, Morisky Medication Adherence Scale-8, Treatment satisfaction, Clinical Sciences, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundPatients' high adherence to medication is indispensable for the management of skin diseases including atopic dermatitis. We previously showed poor medication adherence in Japanese dermatological patients.ObjectiveThis study was conducted to determine the level of adherence to oral or topical medication in Japanese patients with atopic dermatitis, attempting to characterize the socioeconomic status of those patients with poor adherence.MethodsA web questionnaire survey on demographic data as well as adherence level was conducted on patients registered in the monitoring system. Adherence level was assessed with Morisky Medication Adherence Scale-8 (MMAS-8). Among a total of 3096 respondents with dermatological disorders, data of 1327 subjects with atopic dermatitis were extracted and analyzed.ResultsMore than 80% of subjects felt that both oral and topical medications were safe and efficacious, while less than 60% of them were satisfied with their treatment. Levels of adherence to oral and topical treatments were evaluated with MMAS-8, giving scores of 4.6 and 4.2, respectively. Demographic factors such as gender, marital status, state of employment, alcohol consumption, frequency of hospital visits, and experience of drug effectiveness had a significant impact on the degree of adherence to treatment.ConclusionMedication adherence level in Japanese subjects with atopic dermatitis was relatively low compared with that of other chronic diseases. Our survey has characterized patients with poor adherence, who are good targets for interventions to maximize potentially limited healthcare resources.

Published
2015

5. Poor adherence to medication as assessed by the Morisky Medication Adherence Scale‐8 and low satisfaction with treatment in 237 psoriasis patients

Author

Saeki, Hidehisa, Imafuku, Shinichi, Abe, Masatoshi, Shintani, Yoichi, Onozuka, Daisuke, Hagihara, Akihito, Katoh, Norito, Murota, Hiroyuki, Takeuchi, Satoshi, Sugaya, Makoto, Tanioka, Miki, Kaneko, Sakae, Masuda, Koji, Hiragun, Takaaki, Inomata, Naoko, Kitami, Yuki, Tsunemi, Yuichiro, Abe, Shinya, Kobayashi, Miwa, Morisky, Donald E, and Furue, Masutaka

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Psoriasis, Clinical Research, 7.1 Individual care needs, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Management of diseases and conditions, Skin, Administration, Topical, Adult, Aged, Aged, 80 and over, Dermatologic Agents, Female, Humans, Japan, Male, Medication Adherence, Middle Aged, Patient Satisfaction, Skin Diseases, Surveys and Questionnaires, Young Adult, adherence, Morisky Medication Adherence Scale-8, psoriasis, sociomedical factor, treatment satisfaction, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Previously we assessed the medication adherence for oral and topical remedies by a translated Japanese version of the Morisky Medication Adherence Scale-8 (MMAS-8) together with socioeconomic backgrounds in 3096 Japanese dermatological patients, and found the medication adherence, especially to topical drugs, was poor in these patients. In order to elucidate the disease-specific sociomedical factors, we further sub-analyzed the medication adherence in 237 psoriasis patients and compared it with that in other dermatological diseases such as atopic dermatitis, urticaria or tinea. This study was conducted among patients registered in monitoring system and 3096 eligible patients were enrolled. Our web-based questionnaire included the following items such as age, sex, annual income, main health-care institution, experience of effectiveness by oral or topical medication, overall satisfaction with treatment, and MMAS-8 for oral or topical medication. Mean adherence score by MMAS-8 was 5.2 for oral and 4.3 for topical medication. More patients with psoriasis used a university hospital and fewer used a private clinic compared with those with the other skin disease patients. Experience of drug effectiveness by oral medication and overall satisfaction with treatment was lower in psoriasis patients than in other patients. In oral medication, significantly better adherence was observed in those of higher age and with higher annual income. The adherence to medication, especially to topical drugs, was poor in 237 psoriasis patients. We speculated that some severe psoriasis patients were not sufficiently treated systemically and were resistant to topical therapy, leading to poor adherence.

Published
2015

6. Favorable efficacy of S‐1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region

Author

Izumi, Teruaki, primary, Teramoto, Yukiko, additional, Kamimura, Anna, additional, Doi, Reiichi, additional, Takai, Sayaka, additional, Mori, Tatsuhiko, additional, Koizumi, Shigeru, additional, Kawahara, Yu, additional, Aitake, Urara, additional, Lei, Xiaofeng, additional, Inomata, Naoko, additional, Inafuku, Kazuhiro, additional, and Nakamura, Yasuhiro, additional

Published
2023
Full Text
View/download PDF

11. Favorable efficacy of S‐1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region.

Author

Izumi, Teruaki, Teramoto, Yukiko, Kamimura, Anna, Doi, Reiichi, Takai, Sayaka, Mori, Tatsuhiko, Koizumi, Shigeru, Kawahara, Yu, Aitake, Urara, Lei, Xiaofeng, Inomata, Naoko, Inafuku, Kazuhiro, and Nakamura, Yasuhiro

Abstract

Cutaneous squamous cell carcinoma is usually treated with surgery; however, locoregionally advanced cutaneous squamous cell carcinoma can be difficult to resect. Although recent guidelines from Western countries recommend using anti–programmed cell death protein 1 (PD‐1) antibodies, including cemiplimab and pembrolizumab, there are no approved anti–PD‐1 antibodies for locoregional cutaneous squamous cell carcinoma in Asian countries. S‐1 is an oral drug with a low incidence of severe toxicity that can be used for head and neck cancers, including head and neck locoregional cutaneous squamous cell carcinoma, in Japan. We retrospectively evaluated patients with head and neck locoregional cutaneous squamous cell carcinoma treated with S‐1 at two Japanese institutions (2008–2022). The initial dosage was determined by the body surface area (<1.25 m2: 80 mg/day, 1.25–1.5 m2: 100 mg/day, ≥1.5 m2: 120 mg/day) for 28 consecutive days. The outcome measures were objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS). Fourteen patients were included. The ORR was 78%, and the complete response (CR) rate was 64.3%. The median PFS and OS were not reached (NR) (95% confidence interval [CI], 5.9 months–NR) and NR (95% CI, 13.8 months–NR), respectively. The 12‐month PFS and OS rates were 51% and 85%, respectively. Six of the nine patients who achieved CR showed no recurrence during the follow‐up period (median follow‐up, 24.7 months). After CR, three patients experienced recurrence. Among these, two resumed S‐1 treatment and subsequently underwent salvage surgery, resulting in a sustained absence of recurrence. One patient developed lung metastasis and died, although S‐1 therapy was resumed. Only one patient (7.1%) developed grade 3 anemia. S‐1 showed favorable efficacy and low toxicity in patients with head and neck locoregionally advanced cutaneous squamous cell carcinoma. S‐1 may be a good alternative to the anti–PD‐1 antibody for treating head and neck locoregionally advanced squamous cell carcinoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. ISID0482 - The predictive and diagnostic biomarkers of immune-related adverse events vary by the affected organ

Author

Ito, Haruka, primary, Sueki, Hirohiko, primary, Kokaze, Akatsuki, primary, Yoshimoto, Takahiko, primary, Kubota, Kaoru, primary, Tanaka, Toru, primary, Tsunoda, Takuya, primary, Kubota, Yutaro, primary, Inomata, Naoko, primary, Kato, Yukihiko, primary, Gono, Takahisa, primary, Noguchi, Kazuteru, primary, Matsui, Kiyoshi, primary, Aoyama, Yumi, primary, and Yamamoto, Takenobu, primary

Published
2023
Full Text
View/download PDF

15. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, Emek, Salman, Andaç, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Câmara Agondi, Rosana, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta Fachini Jardim, De Souza Lima, Eduardo Magalhães, Demir, Semra, Dissemond, Joachim, Doğan Günaydın, Sibel, Dorofeeva, Irina, Ensina, Luis Felipe, Ertaş, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Giménez Arnau, Ana M, Godse, Kiran, Gonçalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zając, Alicja, Katelaris, Constance H., Košnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M.Sendhil, Lang, Claudia, Larco-Sousa, José Ignacio, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Calderón llosa, Oscar, Makris, Michael, Marsland, Alexander, Medina, Iris V., Meshkova, Raisa, Bastos Palitot, Esther, Parisi, Claudio A.S., Pickert, Julia, Ramon, Germán D., Rodríguez-Gonzalez, Mónica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sánchez Caraballo, Jorge Mario, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, E, Song, Zhiqiang, Soria, Angèle, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B.A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yücel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, Maurer, Marcus, Universitat Autònoma de Barcelona, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Salman, A., Cherrez-Ojeda, I., Criado, P. R., Peter, J., Comert-Ozer, E., Abuzakouk, M., Agondi, R. C., Al-Ahmad, M., Altrichter, S., Arnaout, R., Arruda, L. K., Asero, R., Bauer, A., Ben-Shoshan, M., Bernstein, J. A., Bizjak, M., Boccon-Gibod, I., Bonnekoh, H., Bouillet, L., Brzoza, Z., Busse, P., Campos, R. A., Carne, E., Conlon, N., Criado, R. F., Lima, E. M. D., Demir, S., Dissemond, J., Gunaydin, S. D., Dorofeeva, I., Ensina, L. F., Ertas, R., Ferrucci, S. M., Figueras-Nart, I., Fomina, D., Franken, S. M., Fukunaga, A., Gimenez-Arnau, A. M., Godse, K., Goncalo, M., Gotua, M., Grattan, C., Guillet, C., Inomata, N., Jakob, T., Karakaya, G., Kasperska-Zajac, A., Katelaris, C. H., Kosnik, M., Krasowska, D., Kulthanan, K., Kumaran, M. S., Lang, C., Larco-Sousa, J. I., Lazaridou, E., Leslie, T. A., Lippert, U., Llosa, O. C., Makris, M., Marsland, A., Medina, I. V., Meshkova, R., Palitot, E. B., Parisi, C. A. S., Pickert, J., Ramon, G. D., Rodriguez-Gonzalez, M., Rosario, N., Rudenko, M., Rutkowski, K., Sanchez, J., Schliemann, S., Sekerel, B. E., Serpa, F. S., Serra-Baldrich, E., Song, Z. Q., Soria, A., Staevska, M., Staubach, P., Tagka, A., Takahagi, S., Thomsen, S. F., Treudler, R., Vadasz, Z., Valle, S. O. R., Van Doorn, M. B. A., Vestergaard, C., Wagner, N., Wang, D. H., Wang, L. C., Wedi, B., Xepapadaki, P., Yücel, E., Zalewska-Janowska, A., Zhao, Z. T., Zuberbier, T., Maurer, M., School of Medicine, AII - Infectious diseases, Kocaturk, Emek, Salman, Andac, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Agondi, Rosana Camara, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta F., de Souza Lima, Eduardo M., Demir, Semra, Dissemond, Joachim, Gunaydin, Sibel Dogan, Dorofeeva, Irina, Ensina, Luis Felipe, Ertas, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Gimenez-Arnau, Ana M., Godse, Kiran, Goncalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zajac, Alicja, Katelaris, Constance H., Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Lang, Claudia, Ignacio Larco-Sousa, Jose, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Llosa, Oscar Calderon, Makris, Michael, Marsland, Alexander, Medina, Iris, V, Meshkova, Raisa, Palitot, Esther Bastos, Parisi, Claudio A. S., Pickert, Julia, Ramon, German D., Rodriguez-Gonzalez, Monica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sanchez, Jorge, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, Esther, Song, Zhiqiang, Soria, Angele, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B. A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yucel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, and Maurer, Marcus

Subjects
Male, 0301 basic medicine, STRESS, Exacerbation, UCARE, pandemije, Medizin, Omalizumab, SERUM, chronic urticaria, 0302 clinical medicine, Pandemic, Health care, Immunology and Allergy, Chronic Urticaria, treatment, Chronic urticaria, COVID-19, Cyclosporine, SARS-CoV-2, Treatment, zdravljenje, ASSOCIATION, Middle Aged, cyclosporine, omalizumab, pandemic, kronična urtikarija, INFECTIONS, GA(2)LEN, Female, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Coronavirus disease 2019 (COVID-19), Immunology, udc:616-097, pandemics, ciklosporin, Young Adult, 03 medical and health sciences, Patient referral, medicine, Humans, In patient, Patient Reported Outcome Measures, Aged, Internet, business.industry, DEFINITION, Medicine, Allergy, Cross-Sectional Studies, 030104 developmental biology, 030228 respiratory system, Emergency medicine, business
Abstract

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: the COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation., Novartis; Sanofi; Menarini Universidad Espiritu Santo; Takeda; Allakos; AstraZeneca; CSL Behring; Genentech; Pharming; GSK; Shire/Takada; BioCryst; ResTORbio; Pearl Therapeutics, CVS Health; Law offices of Levin; Riback; Adelman; Flangel; Vedder Price; Fresenius; Taiho; Kyowa Kirin; Tanabe; Korin; Uriach Pharma; Instituto Carlos III FEDER; Menarini; Amgen; Thermo Fisher; Avene; ALK‐Abello; Bencard/Allergy Therapeutics; Celgene; Allergopharma; Faes Farma; AbbVie; Janssen; Leo Pharma; Lilly; Roche; Genesis; Menlo Therapeutics; UCB; Pfizer; Almirall; Galderma; Allergika; Beiersdorf; Biocryst; Biogen Idec; BMS; Boehringer‐Ingelheim; Eli‐Lilly; Galderma; Hexal; Klosterfrau; LEO‐Pharma; LETI‐Pharma; L´Oreal; Medice; Octapharma; Pflüger; Pharming; Regeneron; Shire; ALK‐Abello; Fraunhofer‐IZI Leipzig; Hautnetz Leipzig/Westsachsen; MSD; HAL‐Allergy; Bencard; Nestle; Nutricia; Bayer Health Care; FAES; Henkel; Allakos; Argenx; Genentech Menarini; Moxie; Aralez; Celldex

Published
2021
Full Text
View/download PDF

22. Adherence to oral and topical medication in 445 patients with tinea pedis as assessed by the Morisky Medication Adherence Scale-8

Author

Tsunemi, Yuichiro, Abe, Shinya, Kobayashi, Miwa, Kitami, Yuki, Onozuka, Daisuke, Hagihara, Akihito, Takeuchi, Satoshi, Murota, Hiroyuki, Sugaya, Makoto, Masuda, Koji, Hiragun, Takaaki, Kaneko, Sakae, Saeki, Hidehisa, Shintani, Yoichi, Tanioka, Miki, Imafuku, Shinichi, Abe, Masatoshi, Inomata, Naoko, Morisky, Donald E., Furue, Masutaka, and Katoh, Norito

Published
2015
Full Text
View/download PDF

23. Adrenaline autoinjector is under-prescribed in typical cold urticaria patients living in tropical climate countries

Author

Bizjak, Mojca, primary, Košnik, Mitja, additional, Dinevski, Dejan, additional, Francis Thomsen, Simon, additional, Fomina, Daria, additional, Borzova, Elena, additional, Kulthanan, Kanokvalai, additional, Meshkova, Raisa, additional, Aarestrup, FernandoM, additional, Melina Ahsan, Dalia, additional, Al-Ahmad, Mona, additional, Altrichter, Sabine, additional, Bauer, Andrea, additional, Brockstädt, Maxi, additional, Costa, Célia, additional, Demir, Semra, additional, Fachini Criado, Roberta, additional, Felipe Ensina, Luis, additional, Gelincik, Asli, additional, Giménez-Arnau, Ana Maria, additional, Gonçalo, Margarida, additional, Gotua, Maia, additional, Grønlund Holm, Jesper, additional, Inomata, Naoko, additional, Kasperska-Zajac, Alicja, additional, Khoshkhui, Maryam, additional, Klyucharova, Aliya, additional, Kocatürk, Emek, additional, Lu, Rongbiao, additional, Makris, Michael, additional, Maltseva, Natalya, additional, Pasali, Maria, additional, Paulino, Marisa, additional, Pesqué, David, additional, Peter, Jonny, additional, Dario Ramón, German, additional, Ritchie, Carla, additional, Oliveira Rodrigues Valle, Solange, additional, Rudenko, Michael, additional, Sikora, Agnieszka, additional, Wagner, Nicola, additional, Xepapadaki, Paraskevi, additional, Xue, Xiaoyang, additional, Zhao, Zuotao, additional, Terhorst-Molawi, Dorothea, additional, and Maurer, Marcus, additional

Published
2022
Full Text
View/download PDF

24. Risk factors for systemic reactions in typical cold urticaria:Results from the COLD-CE study

Author

Bizjak, Mojca, Košnik, Mitja, Dinevski, Dejan, Thomsen, Simon Francis, Fomina, Daria, Borzova, Elena, Kulthanan, Kanokvalai, Meshkova, Raisa, Ahsan, Dalia Melina, Al-Ahmad, Mona, Altrichter, Sabine, Bauer, Andrea, Brockstädt, Maxi, Costa, Célia, Demir, Semra, Fachini Criado, Roberta, Ensina, Luis Felipe, Gelincik, Asli, Giménez-Arnau, Ana Maria, Gonçalo, Margarida, Gotua, Maia, Holm, Jesper Grønlund, Inomata, Naoko, Kasperska-Zajac, Alicja, Khoshkhui, Maryam, Klyucharova, Aliya, Kocatürk, Emek, Lu, Rongbiao, Makris, Michael, Maltseva, Natalya, Miljković, Jovan, Pasali, Maria, Paulino, Marisa, Pesqué, David, Peter, Jonny, Ramón, German Dario, Ritchie, Carla, Rodrigues Valle, Solange Oliveira, Rudenko, Michael, Sikora, Agnieszka, de Souza Lima, Eduardo M., Wagner, Nicola, Xepapadaki, Paraskevi, Xue, Xiaoyang, Zhao, Zuotao, Terhorst-Molawi, Dorothea, Maurer, Marcus, Bizjak, Mojca, Košnik, Mitja, Dinevski, Dejan, Thomsen, Simon Francis, Fomina, Daria, Borzova, Elena, Kulthanan, Kanokvalai, Meshkova, Raisa, Ahsan, Dalia Melina, Al-Ahmad, Mona, Altrichter, Sabine, Bauer, Andrea, Brockstädt, Maxi, Costa, Célia, Demir, Semra, Fachini Criado, Roberta, Ensina, Luis Felipe, Gelincik, Asli, Giménez-Arnau, Ana Maria, Gonçalo, Margarida, Gotua, Maia, Holm, Jesper Grønlund, Inomata, Naoko, Kasperska-Zajac, Alicja, Khoshkhui, Maryam, Klyucharova, Aliya, Kocatürk, Emek, Lu, Rongbiao, Makris, Michael, Maltseva, Natalya, Miljković, Jovan, Pasali, Maria, Paulino, Marisa, Pesqué, David, Peter, Jonny, Ramón, German Dario, Ritchie, Carla, Rodrigues Valle, Solange Oliveira, Rudenko, Michael, Sikora, Agnieszka, de Souza Lima, Eduardo M., Wagner, Nicola, Xepapadaki, Paraskevi, Xue, Xiaoyang, Zhao, Zuotao, Terhorst-Molawi, Dorothea, and Maurer, Marcus

Abstract

Background: Cold urticaria (ColdU), that is, the occurrence of wheals or angioedema in response to cold exposure, is classified into typical and atypical forms. The diagnosis of typical ColdU relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). We aimed to determine risk factors for ColdA in typical ColdU. Methods: An international, cross-sectional study COLD-CE was carried out at 32 urticaria centers of reference and excellence (UCAREs). Detailed history was taken and CST with an ice cube and/or TempTest® performed. ColdA was defined as an acute cold-induced involvement of the skin and/or visible mucosal tissue and at least one of: cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms. Results: Of 551 ColdU patients, 75% (n = 412) had a positive CST and ColdA occurred in 37% (n = 151) of the latter. Cold-induced generalized wheals, angioedema, acral swelling, oropharyngeal/laryngeal symptoms, and itch of earlobes were identified as signs/symptoms of severe disease. ColdA was most commonly provoked by complete cold water immersion and ColdA caused by cold air was more common in countries with a warmer climate. Ten percent (n = 40) of typical ColdU patients had a concomitant chronic spontaneous urticaria (CSU). They had a lower frequency of ColdA than those without CSU (4% vs. 39%, p =.003). We identified the following risk factors for cardiovascular manifestations: previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, and itchy earlobes. Conclusion: ColdA is common in typical ColdU. High-risk patients require education about their condition and how to use an adrenaline autoinjector.

Published
2022

25. Adrenaline autoinjector is underprescribed in typical cold urticaria patients

Author

Bizjak, Mojca, Košnik, Mitja, Dinevski, Dejan, Thomsen, Simon Francis, Fomina, Daria, Borzova, Elena, Kulthanan, Kanokvalai, Meshkova, Raisa, Aarestrup, Fernando Monteiro, Ahsan, Dalia Melina, Al-Ahmad, Mona, Altrichter, Sabine, Bauer, Andrea, Brockstädt, Maxi, Costa, Célia, Demir, Semra, Criado, Roberta Fachini, Ensina, Luis Felipe, Gelincik, Asli, Giménez-Arnau, Ana Maria, Gonçalo, Margarida, Gotua, Maia, Holm, Jesper Grønlund, Inomata, Naoko, Kasperska-Zajac, Alicja, Khoshkhui, Maryam, Klyucharova, Aliya, Kocatürk, Emek, Lu, Rongbiao, Makris, Michael, Maltseva, Natalya, Pasali, Maria, Paulino, Marisa, Pesqué, David, Peter, Jonny, Ramón, German Dario, Ritchie, Carla, Rodrigues Valle, Solange Oliveira, Rudenko, Michael, Sikora, Agnieszka, Wagner, Nicola, Xepapadaki, Paraskevi, Xue, Xiaoyang, Zhao, Zuotao, Terhorst-Molawi, Dorothea, Maurer, Marcus, Bizjak, Mojca, Košnik, Mitja, Dinevski, Dejan, Thomsen, Simon Francis, Fomina, Daria, Borzova, Elena, Kulthanan, Kanokvalai, Meshkova, Raisa, Aarestrup, Fernando Monteiro, Ahsan, Dalia Melina, Al-Ahmad, Mona, Altrichter, Sabine, Bauer, Andrea, Brockstädt, Maxi, Costa, Célia, Demir, Semra, Criado, Roberta Fachini, Ensina, Luis Felipe, Gelincik, Asli, Giménez-Arnau, Ana Maria, Gonçalo, Margarida, Gotua, Maia, Holm, Jesper Grønlund, Inomata, Naoko, Kasperska-Zajac, Alicja, Khoshkhui, Maryam, Klyucharova, Aliya, Kocatürk, Emek, Lu, Rongbiao, Makris, Michael, Maltseva, Natalya, Pasali, Maria, Paulino, Marisa, Pesqué, David, Peter, Jonny, Ramón, German Dario, Ritchie, Carla, Rodrigues Valle, Solange Oliveira, Rudenko, Michael, Sikora, Agnieszka, Wagner, Nicola, Xepapadaki, Paraskevi, Xue, Xiaoyang, Zhao, Zuotao, Terhorst-Molawi, Dorothea, and Maurer, Marcus

Published
2022

26. Adrenaline autoinjector is underprescribed in typical cold urticaria patients

Author

Bizjak, Mojca, primary, Košnik, Mitja, additional, Dinevski, Dejan, additional, Thomsen, Simon Francis, additional, Fomina, Daria, additional, Borzova, Elena, additional, Kulthanan, Kanokvalai, additional, Meshkova, Raisa, additional, Aarestrup, Fernando Monteiro, additional, Ahsan, Dalia Melina, additional, Al‐Ahmad, Mona, additional, Altrichter, Sabine, additional, Bauer, Andrea, additional, Brockstädt, Maxi, additional, Costa, Célia, additional, Demir, Semra, additional, Criado, Roberta Fachini, additional, Ensina, Luis Felipe, additional, Gelincik, Asli, additional, Giménez‐Arnau, Ana Maria, additional, Gonçalo, Margarida, additional, Gotua, Maia, additional, Holm, Jesper Grønlund, additional, Inomata, Naoko, additional, Kasperska‐Zajac, Alicja, additional, Khoshkhui, Maryam, additional, Klyucharova, Aliya, additional, Kocatürk, Emek, additional, Lu, Rongbiao, additional, Makris, Michael, additional, Maltseva, Natalya, additional, Pasali, Maria, additional, Paulino, Marisa, additional, Pesqué, David, additional, Peter, Jonny, additional, Ramón, German Dario, additional, Ritchie, Carla, additional, Rodrigues Valle, Solange Oliveira, additional, Rudenko, Michael, additional, Sikora, Agnieszka, additional, Wagner, Nicola, additional, Xepapadaki, Paraskevi, additional, Xue, Xiaoyang, additional, Zhao, Zuotao, additional, Terhorst‐Molawi, Dorothea, additional, and Maurer, Marcus, additional

Published
2022
Full Text
View/download PDF

30. Elevated serum osteopontin levels in patients with severe cutaneous adverse drug reactions.

Author

Suzuki, Marie, Koshikawa, Sachiko, Watanabe, Hideaki, Inomata, Naoko, Yamaguchi, Yukie, Aihara, Michiko, and Sueki, Hirohiko

Abstract

Osteopontin (OPN) was initially described as a protein involved in bone metabolism, but the roles played by OPN in the immune system and allergic reactions have attracted increasing attention. Here, we clarify the OPN‐related dynamics of severe cutaneous adverse drug reactions, and assess whether the OPN level has utility for classifying such reactions and serving as a biomarker of severity. Serum OPN levels in patients with drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS), Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and erythema multiforme‐type drug reaction (EM‐DR) were quantified by ELISA. The OPN sources were analyzed by dual immunofluorescence assay of DIHS, SJS/TEN and EM‐DR biopsy specimens. The serum OPN levels of DIHS/DRESS patients (489.1 ± 37.0 ng/mL) and SJS/TEN patients (508.5 ± 47.8 ng/mL) were significantly higher compared with controls (314.4 ± 14.3 ng/mL; p < 0.001). After treatment, the serum OPN level of DIHS/DRESS patients decreased to that of controls. In addition, OPN levels in DIHS/DRESS patients and SJS/TEN patients were higher than in patients with EM‐DR (Mann–Whitney U test, p < 0.05). However, when the Kruskal–Wallis test was used to compare the OPN levels among the three groups of patients, the difference was not significant (p = 0.055). Dual immunofluorescence assay revealed that T lymphocytes and macrophages were the main OPN sources in DIHS, SJS/TEN and EM‐DR patients. These data suggest that the OPN level can be used to evaluate the severity of inflammation in patients experiencing drug reactions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Increased expression of human herpes virus 6 receptor CD134/OX40 in skin lesions of patients with drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.

Author

Lee, Eun Seon, Kiuchi, Yuji, Inomata, Naoko, and Sueki, Hirohiko

Abstract

CD134/OX40, a member of the tumor necrosis factor receptor superfamily, is a cell‐specific receptor for human herpesvirus 6 (HHV‐6) variant B. Patients with drug‐induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) present a significant increase in CD134 expression in peripheral blood CD4+ T cells. We aimed to investigate the frequency of CD134+ CD4 T cells infiltrating skin lesions in patients with DIHS/DRESS and its association with disease severity. We retrospectively included 21 patients with DIHS/DRESS and 11 patients with erythema multiforme (EM). By immunohistochemistry, the frequency of CD134+ CD4 T cells in DIHS was significantly higher than that in EM (p = 0.0083). The DIHS/DRESS severity score was significantly correlated with the frequency of CD134+ CD4 T cells (p = 0.0272); moreover, there was a significant difference between severe and mild/moderate cases. Double immunofluorescence staining revealed that numerous cells presented CD134/CD4 and CD134/Foxp3 overlap in patients with DIHS/DRESS. These data suggest increased susceptibility to HHV‐6 infection at localized skin sites. HHV‐6 may be involved in the mechanism underlying the progression and pathophysiology of DIHS/DRESS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Risk factors for systemic reactions in typical cold urticaria: Results from the COLD‐CE study

Author

Bizjak, Mojca, primary, Košnik, Mitja, additional, Dinevski, Dejan, additional, Thomsen, Simon Francis, additional, Fomina, Daria, additional, Borzova, Elena, additional, Kulthanan, Kanokvalai, additional, Meshkova, Raisa, additional, Ahsan, Dalia Melina, additional, Al‐Ahmad, Mona, additional, Altrichter, Sabine, additional, Bauer, Andrea, additional, Brockstädt, Maxi, additional, Costa, Célia, additional, Demir, Semra, additional, Fachini Criado, Roberta, additional, Ensina, Luis Felipe, additional, Gelincik, Asli, additional, Giménez‐Arnau, Ana Maria, additional, Gonçalo, Margarida, additional, Gotua, Maia, additional, Holm, Jesper Grønlund, additional, Inomata, Naoko, additional, Kasperska‐Zajac, Alicja, additional, Khoshkhui, Maryam, additional, Klyucharova, Aliya, additional, Kocatürk, Emek, additional, Lu, Rongbiao, additional, Makris, Michael, additional, Maltseva, Natalya, additional, Miljković, Jovan, additional, Pasali, Maria, additional, Paulino, Marisa, additional, Pesqué, David, additional, Peter, Jonny, additional, Ramón, German Dario, additional, Ritchie, Carla, additional, Rodrigues Valle, Solange Oliveira, additional, Rudenko, Michael, additional, Sikora, Agnieszka, additional, de Souza Lima, Eduardo M., additional, Wagner, Nicola, additional, Xepapadaki, Paraskevi, additional, Xue, Xiaoyang, additional, Zhao, Zuotao, additional, Terhorst‐Molawi, Dorothea, additional, and Maurer, Marcus, additional

Published
2021
Full Text
View/download PDF

40. Risk factors for systemic reactions in typical cold urticaria: results from the COLD-CE study

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Bizjak, Mojca; Kosnik, Mitja; Dinevski, Dejan; Thomsen, Simon Francis; Fomina, Daria; Borzova, Elena; Kulthanan, Kanokvalai; Meshkova, Raisa; Ahsan, Dalia Melina; Al-Ahmad, Mona; Altrichter, Sabine; Bauer, Andrea; Brockstadt, Maxi; Costa, Celia; Demir, Semra; Criado, Roberta Fachini; Ensina, Luis Felipe; Gelincik, Aslı; Gimenez-Arnau, Ana Maria; Goncalo, Margarida; Gotua, Maia; Holm, Jesper Gronlund; Inomata, Naoko; Kasperska-Zajac, Alicja; Khoshkhui, Maryam; Klyucharova, Aliya; Lu, Rongbiao; Makris, Michael; Maltseva, Natalya; Miljkovic, Jovan; Pasali, Maria; Paulino, Marisa; Pesque, David; Peter, Jonny; Ramon, German Dario; Ritchie, Carla; Valle, Solange Oliveira Rodrigues; Rudenko, Michael; Sikora, Agnieszka; Lima, Eduardo M. Souza; Wagner, Nicola; Xepapadaki, Paraskevi; Xue, Xiaoyang; Zhao, Zuotao; Terhorst-Molawi, Dorothea; Maurer, Marcus, School of Medicine, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Bizjak, Mojca; Kosnik, Mitja; Dinevski, Dejan; Thomsen, Simon Francis; Fomina, Daria; Borzova, Elena; Kulthanan, Kanokvalai; Meshkova, Raisa; Ahsan, Dalia Melina; Al-Ahmad, Mona; Altrichter, Sabine; Bauer, Andrea; Brockstadt, Maxi; Costa, Celia; Demir, Semra; Criado, Roberta Fachini; Ensina, Luis Felipe; Gelincik, Aslı; Gimenez-Arnau, Ana Maria; Goncalo, Margarida; Gotua, Maia; Holm, Jesper Gronlund; Inomata, Naoko; Kasperska-Zajac, Alicja; Khoshkhui, Maryam; Klyucharova, Aliya; Lu, Rongbiao; Makris, Michael; Maltseva, Natalya; Miljkovic, Jovan; Pasali, Maria; Paulino, Marisa; Pesque, David; Peter, Jonny; Ramon, German Dario; Ritchie, Carla; Valle, Solange Oliveira Rodrigues; Rudenko, Michael; Sikora, Agnieszka; Lima, Eduardo M. Souza; Wagner, Nicola; Xepapadaki, Paraskevi; Xue, Xiaoyang; Zhao, Zuotao; Terhorst-Molawi, Dorothea; Maurer, Marcus, and School of Medicine

Abstract

Background: cold urticaria (ColdU), that is, the occurrence of wheals or angioedema in response to cold exposure, is classified into typical and atypical forms. The diagnosis of typical ColdU relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). We aimed to determine risk factors for ColdA in typical ColdU. Methods: an international, cross-sectional study COLD-CE was carried out at 32 urticaria centers of reference and excellence (UCAREs). Detailed history was taken and CST with an ice cube and/or TempTest(R) performed. ColdA was defined as an acute cold-induced involvement of the skin and/or visible mucosal tissue and at least one of: cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms. Results: of 551 ColdU patients, 75% (n = 412) had a positive CST and ColdA occurred in 37% (n = 151) of the latter. Cold-induced generalized wheals, angioedema, acral swelling, oropharyngeal/laryngeal symptoms, and itch of earlobes were identified as signs/symptoms of severe disease. ColdA was most commonly provoked by complete cold water immersion and ColdA caused by cold air was more common in countries with a warmer climate. Ten percent (n = 40) of typical ColdU patients had a concomitant chronic spontaneous urticaria (CSU). They had a lower frequency of ColdA than those without CSU (4% vs. 39%, p = .003). We identified the following risk factors for cardiovascular manifestations: previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, and itchy earlobes. Conclusion: coldA is common in typical ColdU. High-risk patients require education about their condition and how to use an adrenaline autoinjector., GA(2)LEN UCARE Network

Published
2021

45. The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, Emek, primary, Salman, Andaç, additional, Cherrez‐Ojeda, Ivan, additional, Criado, Paulo Ricardo, additional, Peter, Jonny, additional, Comert‐Ozer, Elif, additional, Abuzakouk, Mohamed, additional, Agondi, Rosana Câmara, additional, Al‐Ahmad, Mona, additional, Altrichter, Sabine, additional, Arnaout, Rand, additional, Arruda, Luisa Karla, additional, Asero, Riccardo, additional, Bauer, Andrea, additional, Ben‐Shoshan, Moshe, additional, Bernstein, Jonathan A., additional, Bizjak, Mojca, additional, Boccon‐Gibod, Isabelle, additional, Bonnekoh, Hanna, additional, Bouillet, Laurence, additional, Brzoza, Zenon, additional, Busse, Paula, additional, Campos, Regis A, additional, Carne, Emily, additional, Conlon, Niall, additional, Criado, Roberta F., additional, de Souza Lima, Eduardo M., additional, Demir, Semra, additional, Dissemond, Joachim, additional, Doğan Günaydın, Sibel, additional, Dorofeeva, Irina, additional, Ensina, Luis Felipe, additional, Ertaş, Ragıp, additional, Ferrucci, Silvia Mariel, additional, Figueras‐Nart, Ignasi, additional, Fomina, Daria, additional, Franken, Sylvie M, additional, Fukunaga, Atsushi, additional, Giménez‐Arnau, Ana M., additional, Godse, Kiran, additional, Gonçalo, Margarida, additional, Gotua, Maia, additional, Grattan, Clive, additional, Guillet, Carole, additional, Inomata, Naoko, additional, Jakob, Thilo, additional, Karakaya, Gul, additional, Kasperska‐Zając, Alicja, additional, Katelaris, Constance H, additional, Košnik, Mitja, additional, Krasowska, Dorota, additional, Kulthanan, Kanokvalai, additional, Kumaran, M. Sendhil, additional, Lang, Claudia, additional, Larco‐Sousa, José Ignacio, additional, Lazaridou, Elisavet, additional, Leslie, Tabi Anika, additional, Lippert, Undine, additional, llosa, Oscar Calderón, additional, Makris, Michael, additional, Marsland, Alexander, additional, Medina, Iris V., additional, Meshkova, Raisa, additional, Palitot, Esther Bastos, additional, Parisi, Claudio A.S., additional, Pickert, Julia, additional, Ramon, German D., additional, Rodríguez‐Gonzalez, Mónica, additional, Rosario, Nelson, additional, Rudenko, Michael, additional, Rutkowski, Krzysztof, additional, Sánchez, Jorge, additional, Schliemann, Sibylle, additional, Sekerel, Bulent Enis, additional, Serpa, Faradiba S., additional, Serra‐Baldrich, Esther, additional, Song, Zhiqiang, additional, Soria, Angèle, additional, Staevska, Maria, additional, Staubach, Petra, additional, Tagka, Anna, additional, Takahagi, Shunsuke, additional, Thomsen, Simon Francis, additional, Treudler, Regina, additional, Vadasz, Zahava, additional, Valle, Solange Oliveira Rodrigues, additional, Van Doorn, Martijn B.A., additional, Vestergaard, Christian, additional, Wagner, Nicola, additional, Wang, Dahu, additional, Wang, Liangchun, additional, Wedi, Bettina, additional, Xepapadaki, Paraskevi, additional, Yücel, Esra, additional, Zalewska‐Janowska, Anna, additional, Zhao, Zuotao, additional, Zuberbier, Torsten, additional, and Maurer, Marcus, additional

Published
2020
Full Text
View/download PDF

48. Definition, aims, and implementation of GA 2 LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Maurer, Marcus, primary, Aberer, Werner, additional, Agondi, Rosana, additional, Al‐Ahmad, Mona, additional, Al‐Nesf, Maryam Ali, additional, Ansotegui, Ignacio, additional, Arnaout, Rand, additional, Arruda, Luisa Karla, additional, Asero, Riccardo, additional, Aygören‐Pürsün, Emel, additional, Banerji, Aleena, additional, Bauer, Andrea, additional, Ben‐Shoshan, Moshe, additional, Berardi, Alejandro, additional, Bernstein, Jonathan A., additional, Betschel, Stephen, additional, Bindslev‐Jensen, Carsten, additional, Bizjak, Mojca, additional, Boccon‐Gibod, Isabelle, additional, Bork, Konrad, additional, Bouillet, Laurence, additional, Boysen, Henrik Balle, additional, Brodszki, Nicholas, additional, Broesby‐Olsen, Sigurd, additional, Busse, Paula, additional, Buttgereit, Thomas, additional, Bygum, Anette, additional, Caballero, Teresa, additional, Campos, Régis A., additional, Cancian, Mauro, additional, Cherrez‐Ojeda, Ivan, additional, Cohn, Danny M., additional, Costa, Célia, additional, Craig, Timothy, additional, Criado, Paulo Ricardo, additional, Criado, Roberta F., additional, Csuka, Dorottya, additional, Dissemond, Joachim, additional, Du‐Thanh, Aurélie, additional, Ensina, Luis Felipe, additional, Ertaş, Ragıp, additional, Fabiani, José E., additional, Fantini, Claudio, additional, Farkas, Henriette, additional, Ferrucci, Silvia Mariel, additional, Figueras‐Nart, Ignasi, additional, Fili, Natalia L., additional, Fomina, Daria, additional, Fukunaga, Atsushi, additional, Gelincik, Asli, additional, Giménez‐Arnau, Ana, additional, Godse, Kiran, additional, Gompels, Mark, additional, Gonçalo, Margarida, additional, Gotua, Maia, additional, Gower, Richard, additional, Grumach, Anete S., additional, Guidos‐Fogelbach, Guillermo, additional, Hide, Michihiro, additional, Ilina, Natalia, additional, Inomata, Naoko, additional, Jakob, Thilo, additional, Josviack, Dario O., additional, Kang, Hye‐Ryun, additional, Kaplan, Allen, additional, Kasperska‐Zając, Alicja, additional, Katelaris, Constance, additional, Kessel, Aharon, additional, Kleinheinz, Andreas, additional, Kocatürk, Emek, additional, Košnik, Mitja, additional, Krasowska, Dorota, additional, Kulthanan, Kanokvalai, additional, Kumaran, M. Sendhil, additional, Larco Sousa, José Ignacio, additional, Longhurst, Hilary J., additional, Lumry, William, additional, MacGinnitie, Andrew, additional, Magerl, Markus, additional, Makris, Michael P., additional, Malbrán, Alejandro, additional, Marsland, Alexander, additional, Martinez‐Saguer, Inmaculada, additional, Medina, Iris V., additional, Meshkova, Raisa, additional, Metz, Martin, additional, Nasr, Iman, additional, Nicolay, Jan, additional, Nishigori, Chikako, additional, Ohsawa, Isao, additional, Özyurt, Kemal, additional, Papadopoulos, Nikolaos G., additional, Parisi, Claudio A. S., additional, Peter, Jonathan Grant, additional, Pfützner, Wolfgang, additional, Popov, Todor, additional, Prior, Nieves, additional, Ramon, German D., additional, Reich, Adam, additional, Reshef, Avner, additional, Riedl, Marc A., additional, Ritchie, Bruce, additional, Röckmann‐Helmbach, Heike, additional, Rudenko, Michael, additional, Salman, Andaç, additional, Sanchez‐Borges, Mario, additional, Schmid‐Grendelmeier, Peter, additional, Serpa, Faradiba S., additional, Serra‐Baldrich, Esther, additional, Sheikh, Farrukh R., additional, Smith, William, additional, Soria, Angèle, additional, Staubach, Petra, additional, Steiner, Urs C., additional, Stobiecki, Marcin, additional, Sussman, Gordon, additional, Tagka, Anna, additional, Thomsen, Simon Francis, additional, Treudler, Regina, additional, Valle, Solange, additional, van Doorn, Martijn, additional, Varga, Lilian, additional, Vázquez, Daniel O., additional, Wagner, Nicola, additional, Wang, Liangchun, additional, Weber‐Chrysochoou, Christina, additional, Ye, Young‐Min, additional, Zalewska‐Janowska, Anna, additional, Zanichelli, Andrea, additional, Zhao, Zuotao, additional, Zhi, Yuxiang, additional, Zuberbier, Torsten, additional, Zwiener, Ricardo D., additional, and Castaldo, Anthony, additional

Published
2020
Full Text
View/download PDF

49. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria

Author

Michihiro, Hide, Hae-Sim, Park, Atsuyuki, Igarashi, Young-Min, Ye, Tae-Bum, Kim, Akiko, Yagami, Jooyoung, Roh, Jae-Hyun, Lee, Yuko, Chinuki, Woong, Youn Sang, Hide, Michihiro, Park, Hae-Sim, Igarashi, Atsuyuki, Ye, Young-Min, Kim, Tae-Bum, Yagami, Akiko, Roh, Jooyoung, Lee, Jae-Hyun, Chinuki, Yuko, Youn, Woong Sang, Lee, Soo-Keol, Inomata, Naoko, Choi, Jeong-Hee, Fukunaga, Atsushi, Wang, Junyi, Matsushima, Soichiro, Greenberg, Steve, and Khalil, Sam

Subjects
Adult, Male, medicine.medical_specialty, Urticaria, Dermatology, Omalizumab, Placebo, Biochemistry, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, Quality of life, Double-Blind Method, Japan, Internal medicine, medicine, Humans, Antihistamines, Chronic spontaneous urticaria, Korea, Adverse effect, Molecular Biology, business.industry, Dermatology Life Quality Index, Middle Aged, 030228 respiratory system, Chronic Disease, Asian population, Physical therapy, Female, business, Body mass index, medicine.drug
Abstract

Background: Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population. Objective: The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of omalizumab as add-on therapy for treatment of CSU. Methods: This 26-week multicenter (41 Japanese/Korean sites) study enrolled patients (12-75 years) who were symptomatic despite H1AH treatment. Eligible participants (N = 218) were randomized 1:1:1 to receive three subcutaneous injections of omalizumab 300 mg, 150 mg, or placebo every 4 weeks, followed by 12 weeks of follow-up. Primary outcome was change from baseline to Week 12 (Wk12) in weekly itch severity score (ISS7). Safety was assessed through the summary of adverse events (AEs). Results: Baseline demographics and disease characteristics were generally well balanced across treatment groups. At Wk12, statistically significant decreases from baseline were observed in ISS7 with omalizumab vs placebo (mean changes -10.22, -8.80, and -6.51 for omalizumab 300 mg, 150 mg and placebo; p < 0.001 and p = 0.006 vs placebo, respectively). Overall AE incidence was similar across treatment groups (54.8%, 57.7%, and 55.4% in omalizumab 300 mg, 150 mg, and placebo groups, respectively); nasopharyngitis was the most frequently reported AE in all treatment arms. Conclusion: The POLARIS study demonstrates that omalizumab is an efficacious and well-tolerated add-on therapy in Japanese and Korean H1AH-refractory patients with CSU.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results